CHO Cell Line Development Services For Therapeutic Protein Development

Sartorius’ CHO Cell Line Development Service offers drug developers a robust and reliable solution for producing recombinant therapeutic proteins through high-yielding, stable CHO (Chinese Hamster Ovary) cell lines. This service is grounded in deep scientific expertise and powered by state-of-the-art technologies to reflect decades of continuous innovation in bioprocessing. In 2025, Sartorius proudly celebrates two significant milestones that underscore its leadership in the field: the 10-year anniversary of Cellca becoming part of the Sartorius family and the 20-year anniversary of Cellca’s founding. As a pioneer in cell line development, Cellca has played a pivotal role in shaping industry standards. This rich legacy enables Sartorius to deliver tailored, efficient, and scalable solutions that meet the evolving needs of biopharmaceutical developers worldwide.